Sign In
Buy CLPT
$14.94
+0.360 (+2.47%)
At Close: Jul 31, 2026
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
04:05pm, Thursday, 31'st Oct 2024
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CL
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
04:05pm, Thursday, 17'th Oct 2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation
ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock?
09:21am, Tuesday, 15'th Oct 2024
ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
ClearPoint Neuro Announces Early Repayment of $10 Million Note
04:05pm, Monday, 26'th Aug 2024
ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics
ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)
09:33am, Wednesday, 14'th Aug 2024
ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser th
ClearPoint Neuro: My Favorite Growth Stock
07:39pm, Thursday, 08'th Aug 2024
ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat b
ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript
07:25am, Thursday, 08'th Aug 2024
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Tak
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
07:05pm, Wednesday, 07'th Aug 2024
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Wednesday, 31'st Jul 2024
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The 3 Best Brain-Computer Interface Stocks to Buy Now
09:00am, Saturday, 27'th Jul 2024
Brain-computer interface (BCI) technology creates a direct link between the brain's electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmentin
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
04:05pm, Wednesday, 17'th Jul 2024
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation
7 Growth Stocks That Could 5X in 5 Years
07:00am, Wednesday, 17'th Jul 2024
Growth stocks have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights.
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
04:56am, Wednesday, 10'th Jul 2024
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price
05:11am, Friday, 21'st Jun 2024
ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of n
SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation
